Cited 2 times in
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2024-03-22T05:42:47Z | - |
dc.date.available | 2024-03-22T05:42:47Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198161 | - |
dc.description.abstract | Purpose This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer. Materials and Methods Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events. Results A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%). Conclusion This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Anthracyclines / therapeutic use | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Breast Neoplasms* / pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neutropenia* / chemically induced | - |
dc.subject.MESH | Oxaliplatin / therapeutic use | - |
dc.subject.MESH | Taxoids / adverse effects | - |
dc.title | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Dae-Won Lee | - |
dc.contributor.googleauthor | Bhumsuk Keam | - |
dc.contributor.googleauthor | Keun Seok Lee | - |
dc.contributor.googleauthor | Jin-Hee Ahn | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.contributor.googleauthor | Jin Seok Ahn | - |
dc.contributor.googleauthor | Moon Hee Lee | - |
dc.contributor.googleauthor | Jee Hyun Kim | - |
dc.contributor.googleauthor | Kyung Eun Lee | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Si-Young Kim | - |
dc.contributor.googleauthor | Yeon Hee Park | - |
dc.contributor.googleauthor | Chan-Young Ock | - |
dc.contributor.googleauthor | Kyung-Hun Lee | - |
dc.contributor.googleauthor | Sae-Won Han | - |
dc.contributor.googleauthor | Sung-Bae Kim | - |
dc.contributor.googleauthor | Young Hyuck Im | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Do-Youn Oh | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.identifier.doi | 10.4143/crt.2022.1360 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 36397238 | - |
dc.subject.keyword | Breast neoplasms | - |
dc.subject.keyword | Drug therapy | - |
dc.subject.keyword | Oxaliplatin | - |
dc.subject.keyword | Phase II trial | - |
dc.subject.keyword | S-1 | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 55 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 523 | - |
dc.citation.endPage | 530 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.55(2) : 523-530, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.